Skip to main content
Top
Published in: Digestive Diseases and Sciences 9/2008

01-09-2008 | Review

Body Mass Index and the Efficacy of Acid-Mediating Agents for GERD

Author: Brian C. Jacobson

Published in: Digestive Diseases and Sciences | Issue 9/2008

Login to get access

Abstract

In studies of the association between obesity and gastroesophageal reflux, one subject that has received very little attention is the effect excess body mass may have on the effectiveness of acid-mediating agents. The lack of systematic research may reflect the perceived high clinical efficacy of drugs like proton pump inhibitors. Both proton pump inhibitors and histamine type 2 receptor antagonists have low rates of significant adverse events; if there are differences in the side effect profiles based on BMI, it is unlikely such associations would be detected. Also, while the metabolism of many drugs can be affected by body mass, it is not clear that such a relationship exists with acid-mediating agents. Nevertheless, there is evidence that body mass index may indeed be associated with the efficacy of proton pump inhibitors and histamine type 2 receptor antagonists. This review will examine that evidence and consider some of the possible pharmacokinetic effects that might relate to body mass index.
Literature
3.
go back to reference Lesser G, Deutsch S (1967) Measurement of adipose tissue blood flow and perfusion in man by uptake of 85Kr. J Appl Physiol 23:621–632PubMed Lesser G, Deutsch S (1967) Measurement of adipose tissue blood flow and perfusion in man by uptake of 85Kr. J Appl Physiol 23:621–632PubMed
5.
go back to reference Benedeck IH, Blouin A, McNamara PJ (1984) Serum protein binding and the role of increased alpha 1-acid glycoprotein in moderately obese male subjects. Br J Clin Pharmacol 18:941–946 Benedeck IH, Blouin A, McNamara PJ (1984) Serum protein binding and the role of increased alpha 1-acid glycoprotein in moderately obese male subjects. Br J Clin Pharmacol 18:941–946
6.
go back to reference Andersson T (1996) Pharmacokinetics, metabolism and interactions of acid pump inhibitors: focus on omeprazole, lansoprazole, and pantoprazole. Clin Pharmacokinet 31:9–28PubMed Andersson T (1996) Pharmacokinetics, metabolism and interactions of acid pump inhibitors: focus on omeprazole, lansoprazole, and pantoprazole. Clin Pharmacokinet 31:9–28PubMed
7.
go back to reference Feldman M, Burton ME (1990) Histamine2-receptor antagonists. N Engl J Med 323:1672–1680 Feldman M, Burton ME (1990) Histamine2-receptor antagonists. N Engl J Med 323:1672–1680
8.
11.
go back to reference Hoogerwerf WA, Pasricha PJ (2006) Pharmacotherapy of gastric acidity, peptic ulcers and gastroesophageal reflux disease. In: Goodman and Gillman’s pharmacology, 11th edn. McGraw-Hill, New York Hoogerwerf WA, Pasricha PJ (2006) Pharmacotherapy of gastric acidity, peptic ulcers and gastroesophageal reflux disease. In: Goodman and Gillman’s pharmacology, 11th edn. McGraw-Hill, New York
14.
go back to reference Davis RL, Quenzer RW, Bozigian HP, Warner CW (1990) Pharmacokinetics of ranitidine in morbidly obese women. Drug Intell Clin Pharm 24:1040–1043 Davis RL, Quenzer RW, Bozigian HP, Warner CW (1990) Pharmacokinetics of ranitidine in morbidly obese women. Drug Intell Clin Pharm 24:1040–1043
15.
go back to reference Abernethy DR, Greenblatt DJ, Matlis R, Gugler R (1984) Cimetidine disposition in obesity. Am J Gastroenterol 79:91–94PubMed Abernethy DR, Greenblatt DJ, Matlis R, Gugler R (1984) Cimetidine disposition in obesity. Am J Gastroenterol 79:91–94PubMed
16.
19.
go back to reference Hampel H, Abraham N, El-Serag H (2005) Meta-analysis: obesity and the risk for gastroesophageal reflux disease and its complications. Ann Intern Med 143:199–211PubMed Hampel H, Abraham N, El-Serag H (2005) Meta-analysis: obesity and the risk for gastroesophageal reflux disease and its complications. Ann Intern Med 143:199–211PubMed
20.
go back to reference Jacobson BC, Delemos B, Sun Y et al (2007) Treatment outcomes with rabeprazole (RAB) 20 mg vs. placebo (PBO) in overweight/obese patients with nonerosive reflux disease (NERD): analysis of 2 US multicenter trials. Gastroenterology 132(suppl 2):A-493 (Abstract) Jacobson BC, Delemos B, Sun Y et al (2007) Treatment outcomes with rabeprazole (RAB) 20 mg vs. placebo (PBO) in overweight/obese patients with nonerosive reflux disease (NERD): analysis of 2 US multicenter trials. Gastroenterology 132(suppl 2):A-493 (Abstract)
22.
go back to reference Hetzel DJ, Dent J, Reed WD, Narielvala FM, Mackinnon M, Mc Carthy JH et al (1988) Healing and relapse of severe peptic esophagitis after treatment with omeprazole. Gastroenterology 95:903–912PubMed Hetzel DJ, Dent J, Reed WD, Narielvala FM, Mackinnon M, Mc Carthy JH et al (1988) Healing and relapse of severe peptic esophagitis after treatment with omeprazole. Gastroenterology 95:903–912PubMed
23.
go back to reference Jacobson BC, DeLemos B, Sun Y et al (2007) PPI Efficacy in overweight/obese patients with erosive GERD: rabeprazole (RAB) 20 mg vs. omeprazole (OME) 20 mg. Am J Gastroenterol 102:S150 (Abstract 89) Jacobson BC, DeLemos B, Sun Y et al (2007) PPI Efficacy in overweight/obese patients with erosive GERD: rabeprazole (RAB) 20 mg vs. omeprazole (OME) 20 mg. Am J Gastroenterol 102:S150 (Abstract 89)
24.
go back to reference Pace F, Annese V, Prada A, Zambelli A, Casalini S, Nardini P et al (2005) Italian Rabeprazole Study Group: rabeprazole is equivalent to omeprazole in the treatment of erosive gastro-oesophageal reflux disease. a randomised, double-blind, comparative study of rabeprazole and omeprazole 20 mg in acute treatment of reflux oesophagitis, followed by a maintenance open-label, low-dose therapy with rabeprazole. Dig Liver Dis 37:741–750. doi:10.1016/j.dld.2005.04.026 PubMedCrossRef Pace F, Annese V, Prada A, Zambelli A, Casalini S, Nardini P et al (2005) Italian Rabeprazole Study Group: rabeprazole is equivalent to omeprazole in the treatment of erosive gastro-oesophageal reflux disease. a randomised, double-blind, comparative study of rabeprazole and omeprazole 20 mg in acute treatment of reflux oesophagitis, followed by a maintenance open-label, low-dose therapy with rabeprazole. Dig Liver Dis 37:741–750. doi:10.​1016/​j.​dld.​2005.​04.​026 PubMedCrossRef
25.
go back to reference Sharma P, Vakil N, Monyak JT et al (2007) Effect of obesity on symptom resolution in patients with gastroesophageal reflux disease (GERD). Am J Gastroenterol 102:S139–S140 (Abstract 61) Sharma P, Vakil N, Monyak JT et al (2007) Effect of obesity on symptom resolution in patients with gastroesophageal reflux disease (GERD). Am J Gastroenterol 102:S139–S140 (Abstract 61)
26.
go back to reference Vakil N, Sharma P, Monyak JT et al (2007) Is obesity the cause of reduced healing rates in advanced grades of erosive esophagitis (EE)? Am J Gastroenterol 102:S445 (Abstract 889) Vakil N, Sharma P, Monyak JT et al (2007) Is obesity the cause of reduced healing rates in advanced grades of erosive esophagitis (EE)? Am J Gastroenterol 102:S445 (Abstract 889)
27.
go back to reference Wang WH, Huang JQ, Zheng GF, Wong WM, Lam SK, Karlberg J et al (2005) Is proton pump inhibitor testing an effective approach to diagnose gastroesophageal reflux disease in patients with noncardiac chest pain? a meta-analysis. Arch Intern Med 165:1222–1228. doi:10.1001/archinte.165.11.1222 PubMedCrossRef Wang WH, Huang JQ, Zheng GF, Wong WM, Lam SK, Karlberg J et al (2005) Is proton pump inhibitor testing an effective approach to diagnose gastroesophageal reflux disease in patients with noncardiac chest pain? a meta-analysis. Arch Intern Med 165:1222–1228. doi:10.​1001/​archinte.​165.​11.​1222 PubMedCrossRef
28.
go back to reference Numans ME, Lau J, de Wit NJ, Boris PA (2004) Short-term treatment with proton-pump inhibitors as a test for gastroesophageal reflux disease: a meta-analysis of diagnostic test characteristics. Ann Intern Med 140:518–527PubMed Numans ME, Lau J, de Wit NJ, Boris PA (2004) Short-term treatment with proton-pump inhibitors as a test for gastroesophageal reflux disease: a meta-analysis of diagnostic test characteristics. Ann Intern Med 140:518–527PubMed
32.
go back to reference Pirttiaho HI, Salmela PI, Sotaniemi EA, Pelkonen RO, Pitkänen U, Luoma PV (1984) Drug metabolism in diabetic subjects with fatty livers. Br J Clin Pharmacol 18:895–899PubMed Pirttiaho HI, Salmela PI, Sotaniemi EA, Pelkonen RO, Pitkänen U, Luoma PV (1984) Drug metabolism in diabetic subjects with fatty livers. Br J Clin Pharmacol 18:895–899PubMed
33.
go back to reference Leclercq I, Horsmans Y, Desager JP, Delzenne N, Geubel AP (1998) Reduction in hepatic cytochrome P-450 is correlated to the degree of liver fat content in animal models of steatosis in the absence of inflammation. J Hepatol 28:410–416. doi:10.1016/S0168-8278(98)80314-0 PubMedCrossRef Leclercq I, Horsmans Y, Desager JP, Delzenne N, Geubel AP (1998) Reduction in hepatic cytochrome P-450 is correlated to the degree of liver fat content in animal models of steatosis in the absence of inflammation. J Hepatol 28:410–416. doi:10.​1016/​S0168-8278(98)80314-0 PubMedCrossRef
Metadata
Title
Body Mass Index and the Efficacy of Acid-Mediating Agents for GERD
Author
Brian C. Jacobson
Publication date
01-09-2008
Publisher
Springer US
Published in
Digestive Diseases and Sciences / Issue 9/2008
Print ISSN: 0163-2116
Electronic ISSN: 1573-2568
DOI
https://doi.org/10.1007/s10620-008-0414-8

Other articles of this Issue 9/2008

Digestive Diseases and Sciences 9/2008 Go to the issue
Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin
Prof. Florian Limbourg
Prof. Anoop Chauhan
Developed by: Springer Medicine
Obesity Clinical Trial Summary

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine